AOD-9604 research guide

AOD-9604 in Mixia — Fat Loss Peptide Research Guide

AOD-9604 research guide for Mixia. HGH fragment studied for fat metabolism — covers mechanism, purity standards, COA verification, and how to source AOD-9604.

Skip to Sourcing Guide Order AOD-9604 →

Mixia Guide to AOD-9604 Research

Unlike general health products stocked in every health store, AOD-9604 is distributed via a specialist research supply market that Mixia residents access almost entirely online. What this means for Mixia researchers is that your location matters far less than your ability to evaluate vendor quality — and those verification methods are accessible to anyone. Separating properly characterised AOD-9604 from the rest of the market requires three things: an HPLC chromatogram confirming ≥98% purity, mass spec data establishing the correct molecular weight, and a batch-specific endotoxin panel. Use this guide to verify vendor quality systematically — the standards covered in this guide apply whether you are in Mixia or anywhere else.

The Science Behind AOD-9604

The selectivity profile of different GHS compounds is a critical research consideration. GHRP-6 and GHRP-2 produce GH release alongside cortisol and prolactin elevation — a confounding factor in research designs where these hormones are outcome variables. Ipamorelin was specifically developed for greater GH-release selectivity with minimal cortisol and prolactin elevation, making it more suitable for research designs where GH-specific effects need to be isolated. Hexarelin has the strongest GH-releasing potency in the GHRP class but also the most significant cortisol and prolactin effects. For Mixia researchers designing GH-axis studies, compound selection based on this selectivity profile should precede protocol finalization.

Where to Buy AOD-9604 — A Researcher's Guide

The most effective path to quality AOD-9604 is starting with community forums — peptide forums maintain informal vendor reputation databases that are more trustworthy than marketing materials. When reviewing a AOD-9604 COA, verify: the batch number corresponds to your vial, HPLC purity is ≥98%, mass spec confirms the correct peptide, and endotoxin levels are at acceptable levels for the intended application. The combination of community consensus and independent COA review is the gold standard for AOD-9604 sourcing — community feedback surfaces recurring issues no single purchase reveals, and vice versa. The powdered lyophilised form of AOD-9604 is always preferable to liquid pre-made solutions — lyophilised powder maintains stability for years when frozen, while liquid preparations lose activity within weeks.

Order AOD-9604 — ships to Mixia
COA-verified · International tracking · Research grade
Order Now →

AOD-9604 Research Safety Guide

AOD-9604 is supplied strictly for research applications and is not approved for human use by the FDA or equivalent agencies worldwide — all information here is educational. Reconstitute AOD-9604 with bacteriostatic water at an appropriate concentration for your protocol; a standard 5mg in 2mL gives a 2.5mg/mL solution — providing 25mcg per unit measured on a 100-unit syringe. Verify the endotoxin level in your AOD-9604 batch COA before any injectable research application — look for results reported in endotoxin units per mg or mL and compare against acceptable research limits for your application. For any individual considering AOD-9604 outside a formal research context: seek medical advice first — this compound is not a licensed human medication and its safety characterisation does not match that of regulated drugs.

Frequently Asked Questions

How does AOD-9604 differ from growth hormone?

AOD-9604 contains only the fat-metabolism-relevant fragment of growth hormone (the C-terminal region) without the IGF-1-stimulating N-terminal domain. This means it targets fat cells' beta-adrenergic receptors for lipolytic effects without producing the anabolic IGF-1 signaling associated with full-length GH.

What is the clinical trial history of AOD-9604?

AOD-9604 has undergone multiple Phase II clinical trials for obesity treatment by Metabolic Pharmaceuticals in Australia. The trials showed safety and tolerability but mixed efficacy results for weight loss. It holds GRAS (Generally Recognized As Safe) status from the FDA for food use, which is unusual for research peptides.

What is AOD-9604?

AOD-9604 is a synthetic peptide analogue of the C-terminal fragment of human growth hormone (amino acids 177-191), with an additional tyrosine residue at the N-terminus. It has been studied for fat metabolism effects, specifically lipolysis stimulation and lipogenesis inhibition, without the IGF-1-stimulating effects of full-length GH. It has undergone clinical trials for obesity treatment.

Order AOD-9604 today
COA-verified · International shipping available
Order Now →